texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician
Due to facility issues Texas Oncology–Las Colinas will be closed the week of February 10–14 and Monday, February 17.  We apologize for any inconvenience. View More Important Notifications x

Shiraj Sen, M.D., Ph.D.

Shiraj Sen M.D., Ph.D. Photo

Provider Type: Physician

Specialties:
Board Certifications:
  • Internal Medicine
  • Medical Oncology
Spoken Language: English

Downloads

Education

  • Fellowship in Medical Oncology and Hematology
    The University of Texas MD Anderson Cancer Center, Houston, TX
  • Residency in Internal Medicine
    The University of Texas Southwestern Medical Center, Dallas, TX
  • Medical Doctorate
    The University of Texas Medical School at Houston, Houston, TX
  • Doctor of Philosophy in Biomedical Sciences
    The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Accolades & Memberships

  • American Association of Cancer Research-Bristol Myers Squibb Merit Award (2017)
  • American Society of Clinical Oncology Conquer Cancer Foundation Merit Award (2016, 2018)
  • MD Anderson Cancer Center-Lyndon B. Johnson Hospital Clinical Fellow of the Year Award (2017)
  • MD Anderson Cancer Center Marion D. Edwards Award in Hepatic Oncology (2018)
  • MD Anderson Cancer Center Waun Ki Hong Award for Achievement in Clinical Investigation (2018)
  • Texas Society of Clinical Oncology Merit Award (2015 – 2017)

Publications

Latest News

Research Interest

Dr. Sen's research interest is in developing new, promising drugs to treat cancer through phase I clinical trials. Dr. Sen leads the phase I clinical trial group at NEXT Oncology Dallas and is committed to providing his patients access to the newest cancer treatment options available through phase I clinical trials when standard treatments are no longer effective for them.

Medical Practice

  • Genentech, Medical Oncologist, Medical Director, Product Development Oncology, (October 2020)
  • Sarah Cannon Research Institute at HealthONE, Medical Oncologist, Associate Director, Denver Drug Development Unit, Denver, CO (August 2018 – September 2020)